CD8A and neoplasm: ATRi treatment altered the activation status of tumor-infiltrating CD8 + T cells, resulting in downregulated expression of PD-1, LAG3, and Tim3, along with an increase in IFN-γ-secreting CD8 + T cells, thereby enhancing the cytotoxic activity of these cells [15, 23].